CD36 is known to be an orosensory receptor for dietary long-chain fatty acids, as well as being involved in the chemosensory mechanisms within the human gut. Recent data have demonstrated an ...

Pilatus Biosciences to Present New Data Highlighting Sex-Specific Efficacy of CD36-Targeting Antibody in Colorectal Cancer at ...

Obesity is an alarming threat for all age groups, including children. Fat overconsumption is one of the factors that directly influences this pathology. Recent studies have suggested that a common ...

In life, most of our cells experience a tremendous amount of turnover, on the order of billions every day. As cells age, they stop dividing in a process called senescence, which is a natural part of ...

Scientists from Duke University School of Medicine, the University of Texas Health Science Center at San Antonio (UT Health San Antonio), and the University of Arkansas have found a way to improve the ...

One of the most common causes of death in the developed world is a disease of the major arterial blood vessels that can cause heart attacks and stroke. A critical step in this disease (which is known ...

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, ...

DOVER, Del. & EPALINGES, Switzerland, December 15, 2025--(BUSINESS WIRE)--Pilatus Biosciences Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and ...

Insulin resistance is mainly characteristic for type 2 diabetes, a common disorder that is also a potent risk factor for coronary heart disease. Genetic associations with type 2 diabetes have recently ...

Recently, a study revealed that CD36 expression and palmitoylation are regulated by the tumor suppressor gene EVA1A in hepatocellular carcinoma, making it a key regulator of hepatic lipid metabolism.

Preclinical data demonstrate enhanced efficacy of PLT012 in pMMR colorectal cancer models - Findings position CD36 as a promising metabolic checkpoint target in an underserved patient population DOVER ...